Earnings summaries and quarterly performance for CervoMed.
Executive leadership at CervoMed.
John Alam
Detailed
President and Chief Executive Officer
CEO
KB
Kelly Blackburn
Detailed
Executive Vice President, Clinical Development
MD
Mark De Rosch
Detailed
Executive Vice President, Regulatory and Government Affairs and Program Management
WE
William Elder
Detailed
Chief Financial Officer, General Counsel & Corporate Secretary
Board of directors at CervoMed.
Research analysts covering CervoMed.
Recent press releases and 8-K filings for CRVO.
CervoMed Announces FDA Alignment on Phase 3 Trial for Neflamapimod in DLB
CRVO
New Projects/Investments
Product Launch
- CervoMed Inc. has received FDA alignment on key aspects of its proposed Phase 3 clinical trial design for neflamapimod in Dementia with Lewy Bodies (DLB), which supports a potential New Drug Application (NDA) submission.
- The company plans to initiate a single, global, randomized, double-blind, placebo-controlled Phase 3 clinical trial in approximately 300 patients with DLB in the second half of 2026.
- The primary endpoint for the planned Phase 3 trial will be the worsening of global cognition and function as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB).
- The trial design includes a patient enrichment strategy to exclude those with historical evidence of Alzheimer's disease co-pathology.
- There are currently no approved therapies for DLB in the United States or European Union.
Nov 4, 2025, 12:08 PM
ServoMed Inc. Provides Update on Neflumab for Dementia with Lewy Bodies
CRVO
New Projects/Investments
Product Launch
- ServoMed Inc. (CRVO) is a clinical-stage company focused on developing Neflumab, an investigational orally administered small molecule brain penetrant, for neurological diseases.
- Neflumab's lead indication is Dementia with Lewy Bodies (DLB), a chronic neurodegenerative disease that currently has no approved therapies and represents a large market opportunity, with an estimated 150,000-280,000 patients in the US.
- Phase 2b clinical data for Neflumab in pure DLB patients demonstrated a 52% reduction in the mean change in CDR Sum of Boxes (CDR SB), which increased to 82% in the enriched population, and showed a 67-75% reduced risk of disease progression.
- The company is preparing to initiate a 24-week, 300-patient Phase 3 trial for Neflumab in pure DLB in 2026, following ongoing discussions with the FDA regarding the trial design.
- Neflumab has exhibited a favorable safety profile across all studies to date, with no discontinuations due to severe adverse events.
Oct 22, 2025, 3:25 PM
CervoMed provides update on neflamapimod Phase 3 plans for Dementia with Lewy Bodies
CRVO
New Projects/Investments
Product Launch
Guidance Update
- CervoMed Inc. (CRVO) is a clinical-stage company focused on neurological diseases, with its lead product, neflamapimod, preparing to enter Phase 3 trials for dementia with Lewy bodies (DLB).
- Phase 2 clinical data for neflamapimod demonstrated significant improvements in DLB patients, including a 52% to 82% reduction in the mean change in CDR-Sum of Boxes (CDR-SB) scale and a 67% to 75% reduced risk of progression in pure DLB patients with the effective drug formulation.
- The company plans to initiate its Phase 3 pivotal studies in Q3 2026, which will be a 24-week placebo-controlled randomized study involving approximately 300 pure DLB patients.
- DLB represents a large, untapped market opportunity with no currently approved therapies, and neflamapimod has received Fast-Track designation from the FDA.
- Beyond DLB, CervoMed's pipeline also includes neflamapimod in Phase 2 trials for recovery after stroke and frontotemporal dementia (the latter having orphan drug designation).
Oct 22, 2025, 3:25 PM
CervoMed Inc. Prepares for Phase 3 Trial of Neflamapimod in DLB
CRVO
New Projects/Investments
Product Launch
- CervoMed Inc. (CRVO) is a clinical-stage company focused on neurological diseases of aging, with its lead product, neflamapimod, targeting Dementia with Lewy Bodies (DLB).
- The company is preparing to initiate Phase 3 pivotal studies for neflamapimod in pure DLB, with discussions ongoing with the FDA regarding trial design, including a 24-week placebo-controlled study with approximately 300 patients, aiming for a Q3 2026 start.
- Phase 2 clinical data demonstrated significant improvement in the CDR-Sum of Boxes scale, showing a 52% reduction in the mean change for all participants on the effective drug batch, increasing to an 82% reduction in the enriched pure DLB population, and a 67%-75% reduction in the risk of disease progression.
- DLB represents a large, untapped market opportunity with no currently approved therapies, and neflamapimod has a favorable safety profile across all studies to date.
Oct 22, 2025, 3:25 PM
CervoMed Provides Update on Neflamapimod Development for Dementia with Lewy Bodies
CRVO
New Projects/Investments
- CervoMed Inc. is a clinical-stage company focused on neurological diseases of aging, with its lead product, neflamapimod, preparing to enter Phase 3 trials for dementia with Lewy bodies (DLB).
- The company has reported positive Phase 2 clinical data for neflamapimod in pure DLB patients, demonstrating significant improvements in the CDR-Sum of Boxes scale and a 67% to 75% reduction in the risk of disease progression for patients on the active drug (Batch B) compared to placebo.
- DLB represents a large and untapped commercial market with no currently approved therapies, affecting an estimated 150,000 to 180,000 patients in the US.
- CervoMed is in discussions with the FDA regarding the design of its Phase 3 trial, which is expected to be a 24-week placebo-controlled randomized study involving approximately 300 patients and is anticipated to start in Q3 2026.
- Beyond DLB, CervoMed also has neflamapimod in Phase 2 clinical trials for recovery after stroke and frontotemporal dementia (primary progressive aphasia).
Oct 22, 2025, 3:25 PM
CervoMed Announces Positive New Data from Phase 2b Trial for Neflamapimod in DLB
CRVO
New Projects/Investments
Guidance Update
- CervoMed Inc. announced new data from its Phase 2b RewinD-LB trial, demonstrating neflamapimod's potential as a treatment for dementia with Lewy bodies (DLB).
- The data showed significant improvement in the primary outcome measure, Clinical Dementia Rating Sum of Boxes (CDR-SB), in participants with a low likelihood of Alzheimer's disease co-pathology.
- Neflamapimod also led to a significant reduction in plasma glial fibrillary acidic protein (GFAP), a neurodegeneration biomarker, which correlated with improved CDR-SB scores.
- The company anticipates U.S. Food and Drug Administration (FDA) feedback on its Phase 3 trial design in the fourth quarter of 2025.
Oct 8, 2025, 8:33 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more